FY2025 Full year results
Filed with ASX · · 6 pages · English
Summary by 6ix AI
The company reported a substantial increase in operating revenue, driven by growth in its Software-as-a-Service offerings and strategic investments. The filing outlines the progress of its CT:VQ™ software, which is undergoing FDA review and aims to revolutionize lung imaging without contrast agents. Overall, the report emphasizes the company's commitment to expanding its global footprint and improving respiratory diagnostics through innovative technology.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from 4DMedical
- Appendix 4E - Preliminary Final Report
- 4DMedical secures $10mstrategic invest' from Pro Medicus
- 4DMedical renews 3 year contract with University of Michigan
- Lung Scan Technology Reveals Hidden Secrets of Airway Disease
- 4DMedical contract with Stanford, includes CTVQ
Later from 4DMedical
- 4DMedical receives FDA clearance for CTVQ
- 4DMedical receives $6.0m R&D Tax Incentive
- 4DMedical gains U.S. CMS reimbursement for CTVQ
- 4DMedical's CT: VQ™ receives FDA 510(k) clearance; First-and-only CT-based VQ technology
- S&P DJI Announces September 2025 Quarterly Rebalance
Follow 4DMedical into a list and get an email when it puts out news.
Follow 4DMedical